Published in Blood Weekly, June 13th, 2002
The first full report of the pivotal clinical trial which led to accelerated FDA approval of alemtuzumab in May 2001 was published in the May 15, 2002 issue of Blood, the journal of the American Society of Hematology.
The article also presents follow-up data reporting a 32-month life expectancy among the 33% of trial enrollees who responded to alemtuzumab, said...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.